Cerivastatin sodium, HMG-CoA reductase inhibitor (ab142853)
Key features and details
- Potent HMG-CoA reductase inhibitor
- CAS Number: 143201-11-0
- Purity: > 98%
- Soluble in water
- Form / State: Solid
- Source: Synthetic
Overview
-
Product name
Cerivastatin sodium, HMG-CoA reductase inhibitor -
Description
Potent HMG-CoA reductase inhibitor -
Purity
> 98% -
CAS Number
143201-11-0 -
Chemical structure
Properties
-
Chemical name
(E,3R,5S)-7-[4-(4-Fluorophenyl)-5-(methoxymethyl)-2,6-di(propan-2-yl)pyridin-3-yl]-3,5-dihydroxyhept-6-enoate sodium -
Molecular weight
481.53 -
Molecular formula
C26H33FNNaO5 -
PubChem identifier
23663992 -
Storage instructions
Store at -20°C. Store under desiccating conditions. The product can be stored for up to 12 months. -
Solubility overview
Soluble in water -
Handling
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Refer to SDS for further information.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
-
SMILES
CC(C)C1=C(C(=C(C(=N1)C(C)C)C=CC(CC(CC(=O)[O-])O)O)C2=CC=C(C=C2)F)COC.[Na+] -
Source
Synthetic
-
Research areas
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
References (3)
ab142853 has been referenced in 3 publications.
- Yogev Y et al. Limb girdle muscular disease caused by HMGCR mutation and statin myopathy treatable with mevalonolactone. Proc Natl Acad Sci U S A 120:e2217831120 (2023). PubMed: 36745799
- Dorsch M et al. Statins affect cancer cell plasticity with distinct consequences for tumor progression and metastasis. Cell Rep 37:110056 (2021). PubMed: 34818551
- Saito Y et al. Establishment of Patient-Derived Organoids and Drug Screening for Biliary Tract Carcinoma. Cell Rep 27:1265-1276.e4 (2019). PubMed: 31018139